Cannabis is not a recommended treatment option for patients with attention-deficit/hyperactivity disorder (ADHD) due to a lack of evidence, according to a scoping review.
Researchers from the Federal University of Rio Grande do Sul, Porto Alegre, Brazil, and McMaster University, Ontario, Canada, published their findings in the Journal of Psychiatric Research.
Researchers pulled studies published through June 27, 2022, on the effect of cannabis on ADHD symptomatology and neuropsychiatric outcomes. Sourced from MEDLINE, EMBASE, EMCARE, PsycINFO, Web of Science, Cochrane Library, and Clinicaltrials.gov, the studies included experimental and observational data.
Researchers examined the study population, methods, and key findings for each study.
A total of 39 studies were included, of which 1 had a randomized and placebo-controlled design. This study showed that cannabis had no effect on ADHD. Most other literature included cross-sectional studies that examined ADHD severity and its connection to cannabis use.
Researchers noted that the amount of THC and CBD in many of the included studies were not well measured. Other limitations included “the absence of objective measurements for cannabis exposure and ADHD symptoms, heterogeneous definitions, oversampling, and small sample sizes,” researchers concluded.